Biomedical Engineering Reference
In-Depth Information
8. Evensen JF. The use of porphyrins and non-ionizing radiation for treat-
ment of cancer. Acta Oncol 1995; 8: 1103-10.
9. Keller GS, Razum NJ, Doiron DR. Photodynamic therapy for non-
melanoma skin cancer. Facial Plast Surg 1989; 6: 180-4.
10. Wilson BD, Mang TS, Stoll H, et al. Photodynamic therapy for the
treatment of basal cell carcinoma. Arch Dermatol 1992; 128: 1597-601.
11. Sommer CA, Van Leengoed H, Conti CM, et al. Photodynamic therapy
for cutaneous carcinomas using the second generation photosensitizer
tin ethyl etiopurpurin (SnET2). Lasers Surg Med 1995; 7: 45.
12. Soret JL. Recherches sur l'absorption des rayons ultra violets par
diverses substances. Arch Sci Phys Nat 1883; 10: 430-85.
13. Garbo GM. Purpurins and benzochlorins as sensitizers for photody-
namic therapy. J Photochem Photobiol B 1996; 34: 109-16.
14. Lui H, Hobbs L, Tope WD, et al. Photodynamic therapy of multiple
nonmelanoma skin cancers with verteporfi n and red light-emitting
diodes. Two-year results evaluating tumor response and cosmetic out-
comes. Arch Dermatol 2004; 140: 26-32.
15. Kennedy JC, Pottier RH, Pross DC, et al. Photodynamic therapy with
endogenous protoporphyrin IX: basic principles and present clinical
experiences. J Photochem Photobiol B 1990; 6: 143-8.
16. Peng Q, Warloe T, Berg C, et al. 5-Aminolevulinic acid-based photody-
namic therapy:clinical research and future challenges. Cancer 1997; 79:
2282-308.
17. Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy:
update 2006. Part 1: Photochemistry and photobiology. JEADV 2007;
21: 293-302.
18. Nootheti PK, Goldman MP. Aminolevulinic acid-photodynamic ther-
apy for photorejuvenation. Dermatol Clin 2007; 25: 35-45.
19. Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of
actinic keratosis at varying fl uence rates: assessment of photobleaching,
pain and primary clinical outcome. Br J Dermatol 2004; 151: 1204-12.
20. Nakaseko H, Kobayashi M, Akita Y, et al. Histological changes and
involvement of apoptosis after photodynamic therapy for actinic kera-
toses. Br J Dermatol 2003; 148: 122-7.
21. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endoge-
nous porphyrins after application of 5-aminolevulinic acid. J Am Acad
Dermatol 1993; 28: 17-21.
22. Touma D, Yaar M, Whitehead S, et al. A trial of short incubation,
broad-area photodynamic therapy for facial actinic keratoses and dif-
fuse photodamage. Arch Dermatol 2004; 140: 33-40.
23. Tsai T, Ji HT, Chiang PC, et al. ALA-PDT results in phenotypic changes
and decreased cellular invasion in surviving cancer cells. Lasers Surg
Med 2009; 41: 305-15.
24. Gad F, Viau G, Boushira M, Bertrand R, Bissonnette R. Photodynamic
therapy with 5-aminolevulinic acid induces apoptosis and caspase
activation in malignant T cells. J Cutan Med Surg 2001; 5: 8-13.
25. Kuzelova K, Grebenova D, Pluskalova M, Marinov I, Hrkal Z. Early
apoptotic features of K562 cell death induced by 5-aminolaevulinic
acid-based photodynamic therapy. J Photochem Photobiol B 2004; 73:
67-78.
26. Noodt BB, Berg K, Stokke T, Peng Q, Nesland JM. Apoptosis and
necrosis induced with light and 5-aminolaevulinic acidderived proto-
porphyrin IX. Br J Cancer 1996; 74: 22-9.
27. Webber J, Luo Y, Crilly R, Fromm D, Kessel D. An apoptotic response
to photodynamic therapy with endogenous protoporphyrin in vivo.
J Photochem Photobiol B 1996; 35: 209-11.
28. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy.
J Natl Cancer Inst 1998; 90: 889-905.
29. Henderson BW, Dougherty TJ. How does photodynamic therapy
work? Photochem Photobiol 1992; 55: 145-57.
30. Wieman TJ, Fingar VH. Photodynamic therapy. Surg Clin North Am
1992; 72: 609-22.
31. Klausner JM, Paterson IS, Kobzik L, et al. Oxygen free radicals mediate
ischemia-induced lung injury. Surgery 1989; 105: 192-9.
32. Doukas J, Hechtman HB, Shepro D. Vasoactive amines and eicosanoids
interactively regulate both polymorphonuclear leukocyte diapedesis
and albumin permeability in vitro. Microvasc Res 1989; 37: 125-37.
33. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered
expression of interleukin 6 and interleukin 10 as a result of photody-
namic therapy in vivo. Cancer Res 1997; 57: 3904-9.
34. Korbelik M. Induction of tumor immunity by photodynamic therapy.
J Clin Laser Med Surg 1996; 14: 329-34.
35. Canti G, Lattuada D, Nicolin A, et al. Antitumor immunity induced by
photodynamic therapy with aluminium phthalocyanine and laser
light. Anticancer Drugs 1994; 5: 443-7.
36. MacCormack MA. Photodynamic therapy in dermatology: An update on
applications and outcomes. Semin Cutan Med Surg 2008; 27: 52-62.
37. Nestor MS, Gold MH, Kauvar ANB, et al. The use of photodynamic
therapy in dermatology: Results of a consensus conference. J Drugs
Dermatol 2006; 5: 140-54.
38. Product information (package insert): Levulan R Kerastick TM
(aminolevulinic acid HCl) for topical solution, 20%. Wilmington, MA,
USA: DUSA Pharmaceuticals, Inc, 2009.
39. Fotinos N, Campo MA, Popowycz F, et al. 5-aminolevulinic acid deriv-
atives in photomedicine: characteristics, application and perspectives.
Photochem Photobiol 2006; 82: 994-1015.
40. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology.
J Am Acad Dermatol 2000; 42: 389-413.
41. Gaullier JM, Berg K, Peng Q, et al. Use of 5-aminolevulinic acid esters
to improve photodynamic therapy on cells in culture. Cancer Res 1997;
57: 1481-6.
42. Peng Q, Warloe T, Berg K, et al. 5-aminolevulinic acid-basedd photo-
dynamic therapy. Cancer 1997; 79: 2282-308.
43. Kasche A, Luderschmidt S, Ring J, Hein R. Photodynamic therapy
induces less pain in patients treated with methyl aminolevulinate com-
pared to aminolevulinic acid. J Drugs Dermatol 2006; 5: 353-6.
44. Babilas P, Schreml S, Landthaler M, Szeimies RM. Photodynamic ther-
apy in dermatology: state-of-the-art. Photodermatol Photoimmunol
Photomed 2010; 26: 118-32; Review.
45. Zakhary K, Ellis DAF. Applications of aminolevulinic acid-based pho-
todynamic therapy in cosmetic facial plastic practices. Facial Plast Surg
2005; 21: 110-16.
46. Clark C, Bryden A, Dawe R, et al. Topical 5-aminolevulinic acid
photodynamic therapy for cutaneous lesions: outcome and comparison
of light sources. Photodermatol Photoimmunol Photomed 2003; 19:
134-41.
47. DeHoratius DM, Dover JS. Nonablative tissue remodeling and pho-
torejuvenation. Clin Dermatol 2007; 25: 474-9.
48. Markham T, Collins P. Topical 5-aminolaevulinic acid photody-
namic therapy for extensive scalp actinic keratoses. Br J Dermatol 2001;
145: 502-4.
49. Kalisiak MS, Rao J. Photodynamic therapy for actinic keratoses.
Dermatol Clin 2007; 25: 15-23.
50. Gold MH. Pharmacoeconomic analysis of the treatment of multiple
actinic keratoses. J Drugs Dermatol 2008; 7: 23-5.
51. Stockfl eth E, Kerl H. Guidelines for the management of actinic kerato-
ses. Eur J Dermatol 2006; 16: 599-606.
52. Lehmann P. Methyl aminolaevulinate-photodynamic therapy: A review
of clinical trials in the treatment of actinic keratoses and nonmelanoma
skin cancer. Br J Dermatol 2007; 156: 793-801.
53. Berking C, Herzinger T, Flaig MJ, et al. The effi cacy of photodynamic
therapy in actinic cheilitis of the lower lip: a prospective study of
15 patients. Dermatol Surg 2007; 33: 825-30.
54. Marks R. Epidemiology of nonmelanoma skin cancer and solar kerato-
ses in Australia: a tale of self-immolation in Elysian fi elds. Australas
J Dermatol 1997; 38: S26-9.
55. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol
2002; 146: 1-6.
56. Osborne JE. Skin cancer screening and surveillance. Br J Dermatol
2002; 146: 745-54.
57. Marks R, Rennie G, Selwood TS. Malignant transformation of solar
keratoses to squamous cell carcinoma. Lancet 1988; 1: 795-7.
58. Glogau RG. The risk of progression to invasive disease. J Am Acad
Dermatol 2000; 42: 23-4.
59. Czarnecki D, Meehan CJ, Bruce F, Culjak G. The majority of cutaneous
squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg
2002; 6: 207-9.
60. Cockerell CJ, Wharton JR. New histopathological classifi cation of
actinic keratosis (incipient intraepithelial squamous cell carcinoma).
J Drugs Dermatol 2005; 4: 462-7.
61. Ortonne JP. From actinic keratoses to squamous cell carcinoma.
Br J Dermatol 2002; 146: S20-3.
62. Hurwitz RM, Monger LE. Solar keratosis: an evolving squamous cell
carcinoma. Benign or malignant? Dermatol Surg 1995; 21: 184.
